Literature DB >> 18304877

Invariant NKT cells from HIV-1 or Mycobacterium tuberculosis-infected patients express an activated phenotype.

Carlos J Montoya1, Juan C Cataño, Zoraida Ramirez, Maria T Rugeles, S Brian Wilson, Alan L Landay.   

Abstract

The frequency, subsets and activation status of peripheral blood invariant NKT (iNKT) cells were evaluated in pulmonary tuberculosis (TB) patients and in chronically HIV-1-infected subjects. The absolute numbers of iNKT cells were significantly decreased in TB patients and in HIV-1+ individuals who were antiretroviral therapy naive or had detectable viremia despite receiving HAART. iNKT cell subset analysis demonstrated a decreased percentage of CD4(+) iNKT cells in HIV-1+ subjects, and a decreased percentage of double negative iNKT cells in TB patients. Peripheral blood iNKT cells from HIV-1+ and TB patients had significantly increased expression of CD69, CD38, HLA-DR, CD16, CD56, and CD62L. The expression of CD25 was significantly increased only on iNKT cells from TB patients. These findings indicate that peripheral blood iNKT cells in these two chronic infections show an up-regulated expression of activation markers, suggesting their role in the immune response to infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18304877     DOI: 10.1016/j.clim.2007.12.006

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  35 in total

1.  Dysfunction of natural killer T cells in patients with active Mycobacterium tuberculosis infection.

Authors:  Seung-Jung Kee; Yong-Soo Kwon; Yong-Wook Park; Young-Nan Cho; Sung-Ji Lee; Tae-Jong Kim; Shin-Seok Lee; Hee-Chang Jang; Myung-Geun Shin; Jong-Hee Shin; Soon-Pal Suh; Dong-Wook Ryang
Journal:  Infect Immun       Date:  2012-03-12       Impact factor: 3.441

2.  In-vivo stimulation of macaque natural killer T cells with α-galactosylceramide.

Authors:  C S Fernandez; S Jegaskanda; D I Godfrey; S J Kent
Journal:  Clin Exp Immunol       Date:  2013-09       Impact factor: 4.330

3.  HIV-1 and the immune response to TB.

Authors:  Naomi F Walker; Graeme Meintjes; Robert J Wilkinson
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

4.  Lower numbers of natural killer T cells in HIV-1 and Mycobacterium leprae co-infected patients.

Authors:  Karina I Carvalho; Fernanda R Bruno; Jennifer E Snyder-Cappione; Solange M Maeda; Jane Tomimori; Marilia B Xavier; Patrick A Haslett; Douglas F Nixon; Esper G Kallas
Journal:  Immunology       Date:  2012-05       Impact factor: 7.397

5.  Analysis of invariant natural killer T cells in human paracoccidioidomycosis.

Authors:  Vanessa Gomes Batista; Lúcia Moreira-Teixeira; Maria C Leite-de-Moraes; Gil Benard
Journal:  Mycopathologia       Date:  2011-07-30       Impact factor: 2.574

Review 6.  Presumed guilty: natural killer T cell defects and human disease.

Authors:  Stuart P Berzins; Mark J Smyth; Alan G Baxter
Journal:  Nat Rev Immunol       Date:  2011-02       Impact factor: 53.106

7.  Peripheral NKT cells in simian immunodeficiency virus-infected macaques.

Authors:  Caroline S Fernandez; Angela C Chan; Konstantinos Kyparissoudis; Robert De Rose; Dale I Godfrey; Stephen J Kent
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

8.  Interleukins 15 and 12 in combination expand the selective loss of natural killer T cells in HIV infection in vitro.

Authors:  Venkata Ramanarao Parasa; Anbalagan Selvaraj; Rajasekaran Sikhamani; Alamelu Raja
Journal:  Clin Exp Med       Date:  2014-04-20       Impact factor: 3.984

Review 9.  Nonclassical T cells and their antigens in tuberculosis.

Authors:  Gennaro De Libero; Amit Singhal; Marco Lepore; Lucia Mori
Journal:  Cold Spring Harb Perspect Med       Date:  2014-07-24       Impact factor: 6.915

Review 10.  In search of a new paradigm for protective immunity to TB.

Authors:  Cláudio Nunes-Alves; Matthew G Booty; Stephen M Carpenter; Pushpa Jayaraman; Alissa C Rothchild; Samuel M Behar
Journal:  Nat Rev Microbiol       Date:  2014-03-03       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.